Scarica l'app Stockscreener
1.80
3.74%
-0.07
Pre-mercato:
1.83
0.03
+1.67%
Curis Inc Borsa (CRIS) Ultime notizie
Curis announces pricing of $5.6M public offering - TipRanks
Curis Inc.’s 1-for-20 Reverse Split Raises Liquidity Concerns and Odd-Lot Trading Risks - TipRanks
Curis Stock Price Forecast. Should You Buy CRIS? - StockInvest.us
Curis Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Curis: Q2 Earnings Snapshot - Caledonian Record
CURIS INC 10-Q Summary: Revenue $0 Net income ($8.58M), EPS ($4.02) — 10-Q Summary - TradingView
Curis, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Curis Prices $5.6 Million Public Offering With Healthcare-Focused Institutional Investors - marketscreener.com
CRIS Looks 91.8% Undervalued on GF Value™ Amid Unprofitability C - GuruFocus
Curis prices $5.6 million public offering at $1.50 per share - Investing.com
Curis prices $5.6 million public offering at $1.50 per share By Investing.com - Investing.com UK
Curis, Inc. Announces Pricing of $5.6 Million Public Offering - PR Newswire
CURIS INC SEC Filing (Aug 13, 2026) - Stock Titan
IPO Databook: Curis (CRIS US)Aug 2026 - smartkarma.com
Curis (CRIS) seeks cash via best-efforts stock and warrant offering amid going-concern risk - Stock Titan
Curis Inc (CRIS) Stock News Today - TradingKey
Curis Inc expected to post a loss of $7.84 a shareEarnings Preview - TradingView
Curis, Inc. (CRIS) stock price, news, quote and history - au.finance.yahoo.com
Curis Inc (CRIS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Curis (CRIS) Stock Fair Value Moves Lower After Emavusertib TakeAim Model Rework - finance.yahoo.com
Primer: Curis Inc (CRIS US)Aug 2026 - Smartkarma
Curis Inc expected to post a loss of $7.47 a shareEarnings Preview - TradingView
Curis Regains Nasdaq Compliance, Faces One-Year Monitoring - TipRanks
Curis doses first five patients in leukemia drug study - Investing.com
JonesTrading Maintains Curis(CRIS.US) With Buy Rating, Cuts Target Price to $20 - moomoo.com
CRIS Q2'26 Earnings: EPS estimate is (6.96) USD - TradingView
Curis Inc (CRIS) Institutional Confidence - TradingKey
Curis Inc (CRIS) Cash Flow - TradingKey
Curis Inc (CRIS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Curis Gains As Blood Cancer Drug Progresses, December Readout in Focus - Yahoo Finance
CRIS|Curis Inc|Price:5.190|Chg%:+0.300 - TradingKey
TradingKey - TradingKey
Curis Inc (CRIS) Income Statement - TradingKey
Curis Inc (CRIS) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Curis Inc (CRIS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Curis Inc (CRIS) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
CRIS Maintained by HC Wainwright & Co. -- Price Target Raised to $43.00 - GuruFocus
Curis, Inc. Revenue Breakdown – NASDAQ:CRIS - TradingView
CRIS Q1 2026 Earnings: Significant Earnings Miss Amid Broader ConcernsRevenue Per Share - dars.gov.et
CRIS Q2'26 Earnings: revenue estimate is 1.00M USD - TradingView
Curis stock jumps 11% on positive emavusertib trial data - Investing.com
Curis Strengthens Oncology Pipeline Outlook With Strong TakeAim Lymphoma Response Rates - Benzinga
Curis (CRIS) Stock Sees Fair Value Lift As Analysts Back Leadership And Consumer Focus - Yahoo Finance
Curis Q2 2026: Updated Clinical Data for Emavusertib Trials - grafa.com
Curis stock jumps 11% on positive emavusertib trial data By Investing.com - Investing.com South Africa
Curis Inc Positive Emavusertib Update Transcript - GuruFocus
Curis shares surge after updated emavusertib data strengthens clinical outlook (NASDAQ:CRIS) - Yahoo Finance
Curis reports updated trial data for emavusertib in lymphoma By Investing.com - Investing.com Nigeria
Curis reports updated trial data for emavusertib in lymphoma - Investing.com
Curis Announces Positive Emavusertib Update - PR Newswire
Why did Curis (CRIS) stock soar after hours? - MSN
FRA:CUS1 EPS (Basic): €-20.76 | Significantly Overvalued - GuruFocus
Curis (FRA:CUS1) Graham Number : €N/A (As of Mar. 2026) - GuruFocus
Curis Inc Annual Shareholders Meeting Transcript - GuruFocus
Curis (FRA:CUS1) Marketable Securities : €0.00 Mil (As of Mar. 2026) - GuruFocus
FRA:CUS1 EV-to-EBITDA: 0.69 — 35% Above Median - GuruFocus
Q2 2025 Curis Inc Earnings Call Transcript - GuruFocus
Q1 2026 Curis Inc Earnings Call Transcript - GuruFocus
0.52%
0.07%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):